Cardiac Screening Cost-Effectiveness Model (Population-Level)

Clinical calculation support · Verify results before clinical use

Model inputs

Enter population, screening performance, treatment, cost, and health-outcome assumptions. Use one currency and a consistent costing perspective.

CEAPopulation model
Population and screening performance
Positive whole number of people eligible for screening.
Prevalence in the screened population.
Sensitivity of the initial screening test.
Specificity of the initial screening test.
Costs and treatment assumptions
Cost of screening every eligible person.
Charged for every positive initial screen in this simplified model.
Annual cost for each true-positive individual assumed to receive treatment.
Whole number of years; annual event risk is assumed constant.
Events, health outcomes, and decision threshold
Annual risk before preventive treatment.
Relative reduction in event risk among treated true positives.
Direct acute-care cost assumed avoided per prevented event.
QALYs lost per event, assumed constant.
Applied using an average present-value-factor approximation.
Threshold in the same currency units as costs.

All costs must use the same currency. This is a simplified exploratory model, not a validated decision model for a specific screening programme.

About this model

This deterministic population-level calculator explores how prevalence, screening performance, treatment costs, event risk, and health-outcome assumptions may affect estimated costs and QALYs.

What it calculates

  • Expected true-positive, false-negative, false-positive, and true-negative initial screening results.
  • Screening and confirmatory costs, plus treatment costs over the entered horizon.
  • Approximate events prevented, event costs averted, QALYs gained, and an ICER.
  • A comparison of the estimated ICER with the entered willingness-to-pay threshold.

Key assumptions

  • Initial test sensitivity and specificity are applied to the stated prevalence.
  • Every positive initial screen incurs confirmatory testing cost; confirmatory accuracy is not represented.
  • Screening true positives are treated as the therapy group because confirmatory-test accuracy and treatment uptake are not input parameters.
  • Annual event risk is constant; competing risks and adverse effects are omitted.
  • Discounting uses an average-factor approximation, not a year-by-year state-transition or cohort simulation.

Recommended use

Use for preliminary scenario exploration and teaching. A real programme assessment should define comparators and perspective, use local costs, model confirmatory-test accuracy and treatment uptake, include harms and competing mortality, and evaluate parameter and structural uncertainty.

Method and references

Sanders GD, Neumann PJ, Basu A, et al.Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316(10):1093–1103. DOI: 10.1001/jama.2016.12195; PMID: 27623463.
Husereau D, Drummond M, Augustovski F, et al.Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement. Pharmacoeconomics. 2022;40(6):601–609. PMID: 35015272; DOI: 10.1007/s40273-021-01112-8.
Wilson JMG, Jungner G.Principles and Practice of Screening for Disease. World Health Organization; 1968. WHO publication record.
World Health Organization Regional Office for Europe.Screening: when is it appropriate and how can we get it right? 2020. Official WHO publication.

These sources support general economic-evaluation methods and screening principles. They do not validate this calculator's equations or establish cost-effectiveness of a specific cardiac screening strategy.

Clinical and economic disclaimer: This is an educational, simplified model—not a validated clinical instrument, formal health technology assessment, or recommendation to implement population screening. Outputs depend on user-entered assumptions and omit important clinical, economic, and structural uncertainties. Do not use results alone for clinical, commissioning, reimbursement, or public-health policy decisions.